RT Journal Article
SR Electronic
T1 A New Vaccination Assessment Method and Strategy for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.14.23288579
DO 10.1101/2023.04.14.23288579
A1 Michaelson, James
YR 2023
UL http://medrxiv.org/content/early/2023/04/15/2023.04.14.23288579.abstract
AB Optimizing vaccination to reduce COVID-19 death remains a challenge. A new method, Gompertzian Analysis, examines numbers of infectious disease cases and deaths, by age, on log graphs, capturing COVID-19 Lethality (Deaths/Cases) by the Gompertz Mortality Equation. Gompertzian Analysis revealed that each of the first 4 Vaccination Events (primary and boosters) led to a ∼1/3rd reduction in COVID-19 Lethality. These vaccination reductions in COVID-19 Lethality were cumulative, persistent, and undiminished by variants, while vaccination’s impact on COVID-19 Infectivity (Cases/Population) was fleeting. Primary vaccination and 3 boosters gave an ∼85% reduction in COVID-19 Lethality, with projections suggesting ∼68% fewer deaths (∼267,000 to ∼85,000). Projections also suggest that 6 boosters may offer a ∼96% reduction in COVID-19 Lethality, to the familiar level of influenza, with a ∼91% reduction in COVID-19 deaths, to ∼25,000, fewer than automobile deaths. Gompertzian Analysis provides rational vaccination guidelines by age. Gompertzian Analysis points to a strategy molded by multiple vaccinations reducing COVID-19 Lethality, which is persistent, rather than focusing on reducing COVID-19 Infectivity, which is fleeting. Such a strategy, based on accumulating the necessary number of vaccinations (∼7), and possibly no more, would accept vaccination’s limited ability to prevent infection in exchange for its power to prevent death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The results described were from publicly available datasets, which can be found in the references hereI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe results described were from publicly available datasets, which can be found in the references here